Fosaprepitant Dimeglumine · Regulatory label update

FDA supplemental approval: Fosaprepitant Dimeglumine (Labeling)

U.S. Food and Drug Administration · August 7, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is a regulatory approval record documenting a supplemental labeling change for fosaprepitant dimeglumine (ANDA210625), approved by the FDA on 2026-08-07. The record does not contain clinical trial results, efficacy data, safety data, or comparative outcomes; it is an administrative action only.

What was studied

Regulatory label update.

Key findings

Safety

This record does not contain clinical trial results, efficacy endpoints, or safety data.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval action for a labeling change to fosaprepitant dimeglumine; does not contain clinical trial efficacy or safety data.

Caveats

This record does not contain clinical trial results, efficacy endpoints, or safety data.
The nature of the labeling change is not specified in this record.
No comparator, control arm, or outcome measures are reported.
The record does not disclose what indication, dosage, or clinical context the labeling change addresses.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no clinical study design reported.

Directness

insufficient

Labeling supplement only; clinical endpoints not addressed.

Consistency

insufficient

No comparative or outcome data provided in this record.

Risk of bias

insufficient

Not applicable to regulatory labeling action.

Sample adequacy

insufficient

No trial population or sample size reported.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA210625. This is a regulatory action record, not a clinical study. Brand name: FOSAPREPITANT DIMEGLUMINE. Active ingredient: FOSAPREPITANT DIMEGLUMINE. Sponsor: EUGIA PHARMA. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-08-07. Products: FOSAPREPITANT DIMEGLUMINE, POWDER, INTRAVENOUS, FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Eugia PharmaFosaprepitant Dimeglumine